Shopping Cart 0
Cart Subtotal
USD 0

Incyte Corp (INCY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company's lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. JAKAFI is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company's pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp (INCY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10

Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13

Private Equity 14

TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14

Partnerships 15

Incyte and Foundation Medicine Enter into Agreement 15

Immunovaccine Enters into Agreement with Incyte 16

Incyte and Syros Pharma Enter into Agreement 17

AstraZeneca and MedImmune Expands Agreement with Incyte 18

Bristol-Myers Squibb and Incyte Enter into Agreement 19

Incyte Enters into Research Agreement with Abramson Cancer Center 20

Incyte Enters into Distribution Agreement with GENESIS Pharma 21

Incyte Enters into Agreement with Moffitt Cancer Center 22

Incyte Enters into Agreement with AstraZeneca 23

Incyte Extends Partnership with Merck 24

Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25

Licensing Agreements 26

Incyte Enters into Licensing Agreement with MacroGenics 26

Incyte Enters into Licensing Agreement with Calithera Biosciences 27

Incyte Enters into Licensing Agreement with Merus 29

Incyte Amends Licensing Agreement with ARIAD Pharma 31

Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32

Incyte Amends Licensing Agreement with Agenus 33

Equity Offering 35

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36

Incyte Raises USD650 Million in Public Offering of Shares 37

Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38

Agenus Raises USD35 Million in Private Placement of Common Stock 40

Debt Offering 41

Incyte Completes Private Placement Of Notes Due 2018 For USD 375 Million 41

Incyte Completes Private Placement Of Notes Due 2020 For USD 375 Million 43

Acquisition 45

Gilead Sciences May Acquire Incyte 45

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46

Incyte Corp-Key Competitors 48

Incyte Corp-Key Employees 49

Incyte Corp-Locations And Subsidiaries 50

Head Office 50

Other Locations & Subsidiaries 50

Recent Developments 51

Financial Announcements 51

Sep 30, 2018: Incyte reports 2018 third quarter and nine month financial results and provides updates on key clinical programs 51

Jul 31, 2018: Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs 57

May 01, 2018: Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs 60

Feb 15, 2018: Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs 63

Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 66

May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 68

Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 70

Corporate Communications 73

Sep 06, 2018: Incyte announces Chief Financial Officer David Gryska to retire at the End of 2018 73

Oct 30, 2017: Incyte Names New Member to Its Board of Directors 74

Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 75

Product News 76

06/21/2018: Incyte to Present Data on INCB54828 at 2018 Investor and Analyst Event 76

04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 77

03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 78

03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79

Clinical Trials 80

Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 80

Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 81

Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 82

Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 83

Mar 28, 2017: Calithera to Receive USD 12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Incyte Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10

Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13

TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14

Incyte and Foundation Medicine Enter into Agreement 15

Immunovaccine Enters into Agreement with Incyte 16

Incyte and Syros Pharma Enter into Agreement 17

AstraZeneca and MedImmune Expands Agreement with Incyte 18

Bristol-Myers Squibb and Incyte Enter into Agreement 19

Incyte Enters into Research Agreement with Abramson Cancer Center 20

Incyte Enters into Distribution Agreement with GENESIS Pharma 21

Incyte Enters into Agreement with Moffitt Cancer Center 22

Incyte Enters into Agreement with AstraZeneca 23

Incyte Extends Partnership with Merck 24

Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25

Incyte Enters into Licensing Agreement with MacroGenics 26

Incyte Enters into Licensing Agreement with Calithera Biosciences 27

Incyte Enters into Licensing Agreement with Merus 29

Incyte Amends Licensing Agreement with ARIAD Pharma 31

Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32

Incyte Amends Licensing Agreement with Agenus 33

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36

Incyte Raises USD650 Million in Public Offering of Shares 37

Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38

Agenus Raises USD35 Million in Private Placement of Common Stock 40

Incyte Completes Private Placement Of Notes Due 2018 For USD 375 Million 41

Incyte Completes Private Placement Of Notes Due 2020 For USD 375 Million 43

Gilead Sciences May Acquire Incyte 45

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46

Incyte Corp, Key Competitors 48

Incyte Corp, Key Employees 49

Incyte Corp, Subsidiaries 50

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Incyte Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company's lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. JAKAFI is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company's pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp (INCY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10

Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13

Private Equity 14

TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14

Partnerships 15

Incyte and Foundation Medicine Enter into Agreement 15

Immunovaccine Enters into Agreement with Incyte 16

Incyte and Syros Pharma Enter into Agreement 17

AstraZeneca and MedImmune Expands Agreement with Incyte 18

Bristol-Myers Squibb and Incyte Enter into Agreement 19

Incyte Enters into Research Agreement with Abramson Cancer Center 20

Incyte Enters into Distribution Agreement with GENESIS Pharma 21

Incyte Enters into Agreement with Moffitt Cancer Center 22

Incyte Enters into Agreement with AstraZeneca 23

Incyte Extends Partnership with Merck 24

Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25

Licensing Agreements 26

Incyte Enters into Licensing Agreement with MacroGenics 26

Incyte Enters into Licensing Agreement with Calithera Biosciences 27

Incyte Enters into Licensing Agreement with Merus 29

Incyte Amends Licensing Agreement with ARIAD Pharma 31

Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32

Incyte Amends Licensing Agreement with Agenus 33

Equity Offering 35

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36

Incyte Raises USD650 Million in Public Offering of Shares 37

Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38

Agenus Raises USD35 Million in Private Placement of Common Stock 40

Debt Offering 41

Incyte Completes Private Placement Of Notes Due 2018 For USD 375 Million 41

Incyte Completes Private Placement Of Notes Due 2020 For USD 375 Million 43

Acquisition 45

Gilead Sciences May Acquire Incyte 45

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46

Incyte Corp-Key Competitors 48

Incyte Corp-Key Employees 49

Incyte Corp-Locations And Subsidiaries 50

Head Office 50

Other Locations & Subsidiaries 50

Recent Developments 51

Financial Announcements 51

Sep 30, 2018: Incyte reports 2018 third quarter and nine month financial results and provides updates on key clinical programs 51

Jul 31, 2018: Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs 57

May 01, 2018: Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs 60

Feb 15, 2018: Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs 63

Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 66

May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 68

Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 70

Corporate Communications 73

Sep 06, 2018: Incyte announces Chief Financial Officer David Gryska to retire at the End of 2018 73

Oct 30, 2017: Incyte Names New Member to Its Board of Directors 74

Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 75

Product News 76

06/21/2018: Incyte to Present Data on INCB54828 at 2018 Investor and Analyst Event 76

04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 77

03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 78

03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79

Clinical Trials 80

Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 80

Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 81

Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 82

Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 83

Mar 28, 2017: Calithera to Receive USD 12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Incyte Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10

Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13

TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14

Incyte and Foundation Medicine Enter into Agreement 15

Immunovaccine Enters into Agreement with Incyte 16

Incyte and Syros Pharma Enter into Agreement 17

AstraZeneca and MedImmune Expands Agreement with Incyte 18

Bristol-Myers Squibb and Incyte Enter into Agreement 19

Incyte Enters into Research Agreement with Abramson Cancer Center 20

Incyte Enters into Distribution Agreement with GENESIS Pharma 21

Incyte Enters into Agreement with Moffitt Cancer Center 22

Incyte Enters into Agreement with AstraZeneca 23

Incyte Extends Partnership with Merck 24

Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25

Incyte Enters into Licensing Agreement with MacroGenics 26

Incyte Enters into Licensing Agreement with Calithera Biosciences 27

Incyte Enters into Licensing Agreement with Merus 29

Incyte Amends Licensing Agreement with ARIAD Pharma 31

Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32

Incyte Amends Licensing Agreement with Agenus 33

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36

Incyte Raises USD650 Million in Public Offering of Shares 37

Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38

Agenus Raises USD35 Million in Private Placement of Common Stock 40

Incyte Completes Private Placement Of Notes Due 2018 For USD 375 Million 41

Incyte Completes Private Placement Of Notes Due 2020 For USD 375 Million 43

Gilead Sciences May Acquire Incyte 45

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46

Incyte Corp, Key Competitors 48

Incyte Corp, Key Employees 49

Incyte Corp, Subsidiaries 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Incyte Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.